Guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccines (oral)

World Health Organization - Technical Report Series

Volumn , Issue 941, 2007, Pages 133-188

  Minor, P D ^a   Pombo, M L ^b   Wainwright, W ^c   Wood, D J ^d   Zhou, T Q ^d   Dobbelaer, R ^e   Powell, M ^f   Kieny, M P ^g   Steele, D ^g   Bentsi Enchill, A ^g   Chocarro, L ^g  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b Instituto Nacional de Higiene Rafael Rangel   (Venezuela)

^c PATH   (United States)

^d Family and Community Health   (Switzerland)

^e PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

^f MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; DILUENT; LIVE VACCINE; ROTAVIRUS VACCINE;

BACTERIUM; CELL CULTURE; CERTIFICATION; CLINICAL EVALUATION; CULTURE MEDIUM; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; FUNGUS; GENOTYPE; HUMAN; IMMUNE RESPONSE; MYCOPLASMA; NOMENCLATURE; NONHUMAN; PH; PHENOTYPE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; REVIEW; SAMPLE; SAMPLING; STORAGE; VIRUS CONCENTRATION; VIRUS INFECTION; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 39649121236     PISSN: 05123054     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (25)

1. WHO Guidelines on nonclinical evaluation of vaccines. In: WHO Expert Committee on Biological Standardization. Fifty-fourth report. Geneva, World Health Organization, 2005, Annex 1 (WHO Technical Report Series, No. 927).
2. Guidelines on clinical evaluation of vaccines: regulatory expectations. In: WHO Expert Committee on Biological Standardization. Fifty-second report. Geneva, World Health Organization, 2002, Annex 1 (WHO Technical Report Series, No. 924).
3. WHO Consultative Group. Report of a meeting on quality, safety and efficacy specifications for live attenuated rotavirus vaccines. Mexico City, Mexico, 8-9 February, 2005. Vaccine 23:5478-5487.
4. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: Use of numerical scores for clinical severity of diarrhoeal episodes. Scandinavian Journal of Infectious Diseases, 1990, 22:259-267.
5. Guidelines on transmissible spongiform encephalopathies in relation to biological and pharmaceutical products. Geneva, World Health Organization, 2003 (http://www.who.int.biologicals).
6. Requirements for the use of animal cells as in vitro substrates for the production of biologicals. In: WHO Expert Committee on Biological Standardization. Forty-seventh report. Geneva, World Health Organization, 1998, Annex 1 (WHO Technical Report Series, No. 878).
7. Lebron JA et al. Adaptation of the WHO guideline for residual DNA in parenteral vaccines on continuous cells lines to a limit for oral vaccines. Developments in Biologicals, 2006, 123:35-44.
8. Israel MA et al. Biological activity of polyoma viral DNA in mice and hamsters. Journal of Virology 1979, 29:990-996.
9. Ranheim T et al. Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq®). Journal of Virological Methods, 2006, 131:193-201.
10. Recommendations for the production and control of poliomyelitis vaccine (oral). In: WHO Expert Committee on Biological Standardization. Fiftieth report, Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 904).
11. Guidelines for the production and control of Japanese encephalitis vaccine (live) for human use. WHO Expert Committee on Biological Standardization. Fifty-first report. Geneva, World Health Organization, 2002, Annex 3 (WHO Technical Report Series, No. 910).
12. Guidelines for the production and quality control of candidate tetravalent dengue virus vaccines (live). WHO Expert Committee on Biological Standardization. Fifty-fifth report. Geneva, World Health Organization, 2005, Annex 1 (WHO Technical Report Series, No. 932).
13. Good manufacturing practices for biological products. In: WHO Expert Committee on Biological Standardization. Forty-second report. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No. 822).
14. Laboratory biosafety manual, 3rd ed. Geneva, World Health Organization, 2004.
15. Requirements for the use of animal cells as in vitro substrates for the production of biologicals (Addendum 2003). In: WHO Expert Committee on Biological Standardization. Fifty-fourth report. Geneva, World Health Organization, 2005, Annex 4 (WHO Technical Report Series, No. 927).
16. General requirements for the sterility of biological substances (Requirements for Biological Substances No. 6, revised 1973, amendment 1995). In: WHO Expert Committee on Biological Standardization. Forty-sixth report. Geneva, World Health Organization, 1995, Annex 3 (WHO Technical Report Series No. 872).
17. Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives (Requirements for Biological Substances No. 27, revised 1992). In: WHO Expert Committee on Biological Standardization. Forty-third report. Geneva, World Health Organization, 1994 (WHO Technical Report Series, No. 840).
18. Tests for extraneous agents in viral vaccines for human use (General method No. 2.6.16). European Pharmacopoeia 4th ed, 148-149.
19. Requirements for measles vaccines (Live). WHO Expert Committee on Biological Standardizaton. Thirty-eighth Report. World Health Organization, 1988, Annex 5 (WHO Technical Report Series, No. 771).
20. Good manufacturing practices for pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No. 823).
21. Ward R.L et al. Live vaccine strategies to prevent rotavirus disease. New generation vaccines, 3rd ed. New York, Marcel Dekker, 2004:607-620.
22. Simonsen L et al. More on RotaShield and intussusception: the role of age at the time of vaccination. Journal of Infectious Disease, 2005, 192:S36-43.
23. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: Use of numerical scores for clinical severity of diarrhoeal episodes. Scandinavian Journal of Infectious Diseases, 1990, 22:259-267.
24. Clark et al. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. Journal of Infectious Diseases, 1988, 158:570-587.
25. Guidelines for national authorities on quality assurance for biological products. In: WHO Expert Committee on Biological Standardization. Forty-second report. Geneva, World Health Organization, 1992, Annex 2 (WHO Technical Report Series, No. 822).